Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Meng, Xiujuan ^a   Liu, Sidi ^a   Duan, Juping ^a   Huang, Xun ^a   Zhou, Pengcheng ^a   Xiong, Xinrui ^a   Gong, Ruie ^a   Zhang, Ying ^a   Liu, Yao ^a   Fu, Chenchao ^a   Li, Chunhui ^a   Wu, Anhua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CREC; CSEC; Healthcare associated infection; Risk factors

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; HEMOGLOBIN; LEVOFLOXACIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CHILD; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTHCARE ASSOCIATED INFECTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; MALE; MEDICAL EXAMINATION; MORTALITY; NEWBORN; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; TEACHING HOSPITAL; TRACHEOSTOMY; URINARY TRACT DISEASE; CENTRAL VENOUS CATHETERIZATION; CHINA; CROSS INFECTION; ECONOMICS; ESCHERICHIA COLI INFECTIONS; HEALTH CARE COST; HYPERGLYCEMIA; INCIDENCE; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; UROLOGIC DISEASES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; CHINA; CROSS INFECTION; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; FEMALE; HEALTH CARE COSTS; HEMOGLOBINS; HOSPITALS, TEACHING; HUMANS; HYPERGLYCEMIA; INCIDENCE; INFANT; INFANT, NEWBORN; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TRACHEOSTOMY; UROLOGIC DISEASES; YOUNG ADULT;

EID: 85009508775     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-2176-9     Document Type: Article

References (34)

1. Feng Y, Yang P, Xie Y, Wang X, McNally A, Zong Z. Escherichia coli ofsequence type 3835 carrying bla NDM-1, bla CTX-M-15, bla CMY-42 and bla SHV-12. Sci Rep. 2015;5:12275.
2. Lartigue MF, Poirel L, Poyart C, Reglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 2007;13(2):315-7.
3. Lee BY, Bartsch SM, Wong KF, McKinnell JA, Slayton RB, Miller LG, Cao C, Kim DS, Kallen AJ, Jernigan JA, et al. The Potential Trajectory of Carbapenem-Resistant Enterobacteriaceae, an Emerging Threat to Health-Care Facilities, and the Impact of the Centers for Disease Control and Prevention Toolkit. Am J Epidemiol. 2016;183(5):471-9.
4. Jeon M, Choi S, Kwak YG, Chung J, Lee S, Jeong J, Woo JH, Kim YS. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis. 2008;62(4):402-6.
5. Gulmez D, Woodford N, Palepou MF, Mushtaq S, Metan G, Yakupogullari Y, Kocagoz S, Uzun O, Hascelik G, Livermore DM. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents. 2008;31(6):523-6.
6. Urban C, Bradford PA, Tuckman M, Segal Maurer S, Wehbeh W, Grenner L, Colon Urban R, Mariano N, Rahal JJ. Carbapenem-ResistantEscherichia coli HarboringKlebsiella pneumoniae Carbapenemase β-Lactamases Associated with Long-Term Care Facilities. Clin Infect Dis. 2008;46(11):e127-30.
7. Cui L, Zhao J, Lu J. Molecular characteristics of extended spectrum beta-lactamase and carbapenemase genes carried by carbapenem-resistant Enterobacter cloacae in a Chinese university hospital. Turkish Gunma J Med Sci. 2015;45(6):1321-8.
8. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440-58.
9. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413-31.
10. Shevchenko OV, Mudrak DY, Skleenova EY, Kozyreva VK, Ilina EN, Ikryannikova LN, Alexandrova IA, Sidorenko SV, Edelstein MV. First detection of VIM-4 metallo-beta-lactamase - producing Escherichia coli in Russia. Clin Microbiol Infect. 2012;18(7):E214-7.
11. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-8.
12. Mushtaq S, Irfan S, Sarma JB, Doumith M, Pike R, Pitout J, Livermore DM, Woodford N. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother. 2011;66(9):2002-5.
13. Glasner C, Albiger B, Buist G, Tambic AA, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18(28):9-15.
14. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707.
15. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008;300(24):2911-3.
16. Teo J, Cai Y, Tang S, Lee W, Tan TY, Tan TT, Kwa AL. Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study. Plos One. 2012;7(3):e34254.
17. Nguyen ML, Toye B, Kanji S, Zvonar R. Risk Factors for and Outcomes of Bacteremia Caused by Extended-Spectrum ss-Lactamase-Producing Escherichia coli and Klebsiella Species at a Canadian Tertiary Care Hospital. Can J Hosp Pharm. 2015;68(2):136-43.
18. Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis. 2002;34(12):1564-7.
19. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005;26(4):346-51.
20. Logan LK, Meltzer LA, McAuley JB, Hayden MK, Beck T, Braykov NP, Laxminarayan R, Weinstein RA. Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Infections in Children: A Two-Center Case-Case-control Study of Risk Factors and Outcomes in Chicago. Illinois. J Pediatric Infect Dis Soc. 2014;3(4):312-9.
21. Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016;5(1):1-8.
22. Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, Lee BY: Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2016;23(1):48.e9-48.e16.
23. Candevir UA, Kurtaran B, Inal AS, Komur S, Kibar F, Yapici CH, Bozkurt S, Gurel D, Kilic F, Yaman A, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Med Sci Monit. 2015;21:219-24.
24. Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, Lee LC. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015;4(1):1-7.
25. Han JH, Nachamkin I, Zaoutis TE, Coffin SE, Linkin DR, Fishman NO, Weiner MG, Hu B, Tolomeo P, Lautenbach E. Risk factors for gastrointestinal tract colonization with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol. 2012;33(12):1242-5.
26. Gonzalez-Zorn B, Escudero JA. Ecology of antimicrobial resistance: humans, animals, food and environment. INT MICROBIOL. 2012;15(3):101-9.
27. Zhou P, Xiong X, Li C, Wu A. Association of Length of Stay With Contamination of Multidrug-Resistant Organisms in the Environment and Colonization in the Rectum of Intensive Care Unit Patients in China. Infect Control Hosp Epidemiol. 2016;37(1):120-1.
28. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized Patients. CLIN INFECT DIS. 2002;34(3):340-5.
29. Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, Lee NY, Song JH. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J CLIN MICROBIOL. 2012;50(2):312-7.
30. Cheah AL, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, Kong DC. Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia. BMC Infect Dis. 2014;14(1):1-8.
31. Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother. 2011;66(6):1383-91.
32. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother. 2011;66(7):1600-8.
33. Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect. 2012;45(2):113-9.
34. Stein RA. When less is more: high-dose, short duration regimens and antibiotic resistance. INT J CLIN PRACT. 2008;62(9):1304-5.